Results 161 to 170 of about 11,283,677 (180)

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Blood, 2020
Background: Pts with high-risk LBCL have poor outcomes with R-CHOP chemoimmunotherapy (Sathyanarayanan, et al. ASH 2016. #106), and ≈50% of pts will not achieve long-term disease remission (Coiffier, et al. ASH Ed Program.
S. Neelapu, M. Dickinson, M. Ulrickson, O. Oluwole, A. Herrera, C. Thieblemont, C. Ujjani, Yi Lin, P. Riedell, N. Kekre, S. Vos, Yin Yang, Francesca Milletti, L. Goyal, J. Kawashima, J. Chavez   +15 more
semanticscholar   +1 more source

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

, 2020
8008Background: Advanced stage iNHL, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), is considered incurable as most pts experience multiple relapses (Wang, et al.
C. Jacobson, J. Chavez, A. Sehgal, B. William, J. Muñoz, G. Salles, C. Casulo, Pashna N. Munshi, D. Maloney, S. Vos, R. Reshef, L. Leslie, I. Yakoub-Agha, O. Oluwole, H. Fung, V. Plaks, Y. Yang, Jennifer L. Lee, M. Avanzi, S. Neelapu   +19 more
semanticscholar   +1 more source

Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)

Tumor Biology, 2020
Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for the treatment of adult relapsed/refractory LBCL after ≥ 2 prior lines of therapy. In ZUMA-1, the objective response rate (ORR) was 83% (58%
C. Jacobson, J. Westin, D. Miklos, A. Herrera, Jennifer L. Lee, Judy Seng, J. Rossi, Jennifer Sun, Jinghui Dong, Z. Roberts, R. Vezan, M. Avanzi, F. Locke   +12 more
semanticscholar   +1 more source

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

, 2020
Background: Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is approved for treatment of adult pts with R/R LBCL after ≥ 2 lines of systemic therapy. In the pivotal ZUMA-1 study, axi-cel demonstrated durable responses and
C. Jacobson, F. Locke, D. Miklos, J. Vose, Yi Lin, L. Budde, D. Maloney, S. Jaglowski, P. Riedell, L. Lekakis, M. Perales, Jenny J. Kim, J. Kawashima, Yin Yang, J. Rossi, L. Goyal, S. Neelapu   +16 more
semanticscholar   +1 more source

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

The Lancet, 2021
B. Shah, A. Ghobadi, O. Oluwole, A. Logan, N. Boissel, R. Cassaday, T. Leguay, M. Bishop, M. Topp, D. Tzachanis, K. O'Dwyer, M. Arellano, Yi Lin, M. Baer, G. Schiller, Jae H. Park, M. Subklewe, M. Abedi, M. Minnema, W. Wierda, D. DeAngelo, P. Stiff, D. Jeyakumar, C. Feng, Jinghui Dong, T. Shen, Francesca Milletti, J. Rossi, R. Vezan, B. K. Masouleh, R. Houot   +30 more
semanticscholar   +1 more source

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood, 2018
Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor long-term outcomes (El Fakih et al. Hematol Oncol Stem Cell Ther. 2017; Oriol et al. Haematologica.
W. Wierda, M. Bishop, O. Oluwole, A. Logan, M. Baer, W. Donnellan, K. O'Dwyer, J. Castro, G. Schiller, H. Holmes, M. Abedi, A. Ghobadi, M. Arellano, Adriana K Malone, J. Pagel, A. Mardiros, T. Shen, R. Vezan, R. Jain, B. Shah   +19 more
semanticscholar   +1 more source

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

The Lancet Oncology, 2021
C. Jacobson, J. Chavez, A. Sehgal, B. William, J. Muñoz, G. Salles, Pashna N. Munshi, C. Casulo, D. Maloney, S. de Vos, R. Reshef, L. Leslie, I. Yakoub-Agha, O. Oluwole, H. Fung, J. Rosenblatt, J. Rossi, L. Goyal, V. Plaks, Yin Yang, R. Vezan, M. Avanzi, S. Neelapu   +22 more
semanticscholar   +1 more source

Early Makuria Research Project. El-Zuma Cemetery

Azania: Archaeological Research in Africa, 2023
openaire   +1 more source

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

, 2016
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, Mitchell R. Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, J. Wiezorek, W. Go   +36 more
semanticscholar   +1 more source

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

Nature Cancer
Paolo Strati, Lori A. Leslie, P. Shiraz, L. Budde, O. Oluwole, M. Ulrickson, Aravind Ramakrishnan, Teresa Zhang, Jennifer Sun, Francesca Milletti, J. Kanska, Rhine Shen, Frank Neumann, Hairong Xu, Krish Patel   +14 more
semanticscholar   +1 more source